U.S. markets closed
  • S&P 500

    -75.65 (-1.46%)
  • Dow 30

    -475.84 (-1.24%)
  • Nasdaq

    -267.10 (-1.62%)
  • Russell 2000

    -39.43 (-1.93%)
  • Crude Oil

    +0.43 (+0.51%)
  • Gold

    -12.50 (-0.53%)
  • Silver

    -0.28 (-0.99%)

    -0.0085 (-0.79%)
  • 10-Yr Bond

    -0.0770 (-1.68%)

    -0.0104 (-0.83%)

    +0.0370 (+0.02%)
  • Bitcoin USD

    -3,068.18 (-4.38%)
  • CMC Crypto 200

    0.00 (0.00%)
  • FTSE 100

    +71.78 (+0.91%)
  • Nikkei 225

    +80.92 (+0.21%)

The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction to catalytic events.

ChemoCentryx Inc (NASDAQ: CCXI) nearly tripled in a single session in reaction to positive Phase 3 data for drug to treat rare inflammatory disease.

The Medicines Company (NASDAQ: MDCO) was another standout gainer, adding about 22% Monday, on a deal to be bought by Novartis AG (NYSE: NVS).

Here are the key catalysts for the unfolding week.


  • International Alliance of Amyotrophic Lateral Sclerosis/Motor Neurone Disease, or ALS/MND, Annual Meeting – Dec. 1-2 in Perth, Australia

  • 34th World Cardiology Conference – Dec. 2-3 in Barcelona, Spain

  • Annual Congress on Antibiotics and Antimicrobial Resistance - Dec. 2-3 in Paris, France

  • 6th Annual Conference on Stroke and Neurological Disorders - Dec. 2-3 in Rome, Italy

  • 10th International Conference on Immunology & Immunogenetics - Dec. 2-3 in London

  • 12th Clinical Trials On Alzheimer's Disease, or CTAD – Dec. 4-7 in San Diego, California

  • Piper Jaffray 31st Annual Healthcare Conference – Dec. 3-5 in New York City

  • Evercore ISI HealthCONx Conference – Dec. 3-5 in Boston, Massachusetts

  • 2nd Global Conference on Cardiovascular Research and Clinical Cardiology – Dec. 6-7 in Montreal, Canada

  • American Epilepsy Society, or AES, 2019 Annual Meeting – Dec. 6-10 in Baltimore, Maryland

  • 61st American Society of Hematology, or ASH, Annual Meeting – Dec. 7-10 in Orlando, Florida


The FDA is scheduled to give its verdict on Roche Holdings AG Basel ADR's (OTC: RHHBY) Tecentriq in combination with Bristol-Myers Squibb Co's (NYSE: BMY) chemo medications Carboplatin and Abraxane in patients with metastatic non-squamous NSCLC, who do not have EGFR or ALK genomic tumor aberrations. The PDUFA action date is fixed for Monday.

Clinical Readouts CTAD Presentations

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) – detailed Phase 3 data for pimavanserin in dementia-related psychosis (Wednesday)

Biogen Inc (NASDAQ: BIIB) – Detailed data from the Phase 3 EMERGE study of aducanumab in Alzheimer's disease (Thursday)

Cassava Sciences Inc (NASDAQ: SAVA) – Phase 2a data for PTI-125 in Alzheimer's disease (Thursday)

Alector Inc (NASDAQ: ALEC) – Phase 1 data for AL002, a monoclonal antibody, in Alzheimer's disease (Friday)

International Alliance of ALS/MND Annual Meeting Presentations

Cytokinetics, Inc. (NASDAQ: CYTK) – Responder and subgroup analyses of data from the Phase 2 study of Reldesemtiv in ALS (Thursday)

See Also: A Deep Dive Into Aquestive Following The FDA's Approval Of Riluzole

AES Annual Meeting Presentations

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) – Phase 3 data for Epidiolex in tuberous sclerosis leukemia (Saturday)

ASH Presentations

(Scheduled for Saturday)

Magenta Therapeutics Inc (NASDAQ: MGTA) – initial Phase 1 data for MGTA-145 in healthy volunteers

Bristol-Myers Squibb – Phase 1 data for liso-cel, or JCAR017, in relapsed/refractory B cell non-Hodgkin lymphoma

Fortress Biotech (NASDAQ: FBIO) and Mustang Bio Inc (NASDAQ: MBIO) – Phase 1/2 data for MB-107 in X-linked severe combined immunodeficiency

Sierra Oncology Inc (NASDAQ: SRRA – Phase 3 data for momelotinib in myelofibrosis

Actinium Pharmaceuticals Inc (NYSE: ATNM) – Phase 3 data for lomab-B in acute myeloid luekemia

bluebird bio Inc (NASDAQ: BLUE) – Phase 1/2 data for LentiGlobin in sickle cell disease

Morphosys Ag (NASDAQ: MOR) – Phase 2 data for MOR208 and Gilead Sciences, Inc. (NASDAQ: GILD)'s Zydelig in chronic lymphocytic leukemia Unum Therapeutics Inc (NASDAQ: UMRX) – Phase 1 data for ACTR707 with Roche's Rituxan in CD20 positive non-Hodgkin lymphoma and Phase 1 data for ACTR087 plus Rituxan, also in non-Hodgkin lymphoma

Verastem Inc (NASDAQ: VSTM) – Phase 2 data for duvelisib in peripheral T-cell lymphoma

Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL) – interim Phase 1 data for AUTO3 in relapsed/refractory diffuse large B-cell lymphoma and updated Phase 1 data for AUT01 in acute lymphoblastic leukemia

TrovaGene Inc (NASDAQ: TROV) – Phase 1/2 data for ovansertib in acute myeloid leukemia

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) – initial Phase 1 data for CYC065 plus AbbVie Inc (NYSE: ABBV)'s venetoclax in chronic lymphocytic leukemia

Oncternal Therapeutics Inc (NASDAQ: ONCT) – Phase 1/2 data for cirmtuzumab plus AbbVie's ibrutinib in chronic lymphocytic leukemia and mantle cell lymphona

Sangamo Therapeutics Inc (NASDAQ: SGMO) – Phase 1/2 data for SB-525 in hemophilia A

Acceleron Pharma Inc (NASDAQ: XLRN) and Bristol-Myers Squibb – Phase 2 data for luspatercept in hemophilia A

IPO Quiet Period Expirations

Centogene N.V./EQ (NASDAQ: CNTG)
Galera Therapeutics Inc (NASDAQ: GRTX)
CNS Pharmaceuticals Inc (NASDAQ: CNSP)
89bio Inc (NASDAQ: ETNB)


See more from Benzinga

© 2019 Benzinga does not provide investment advice. All rights reserved.